Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 · View on ClinicalTrials.gov ↗
Study Summary
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Conditions Studied
Interventions
- DRUG NKT3964
Study Locations (19)
California
- University of California - Los Angeles — Los Angeles
- UCSF — San Francisco
Florida
- Florida Cancer Specialists & Research Institute — Lake Mary
- AdventHealth Cancer Institute — Orlando
Georgia
- Emory Winship Cancer Institute — Atlanta
- Augusta University — Augusta
Pennsylvania
- Sidney Kimmell Cancer Center - Jefferson Health — Philadelphia
- UPMC — Pittsburgh
Texas
- NEXT Oncology — Austin
- UT Southwestern — Dallas
Virginia
- University of Virginia — Charlottesville
- NEXT Virginia — Fairfax
Arkansas
- University of Arkansas Medical School — Little Rock
Colorado
- SCRI at HealthOne — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586957
The ClinicalTrials.gov registry entry for NCT06586957 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NiKang Therapeutics, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention — of which NKT3964 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06586957 reports 19 study locations spanning 13 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06586957 about?
NCT06586957 is a clinical study titled "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors". The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expan...
What is the current status of trial NCT06586957?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-09-19. Estimated completion is 2029-05.
What conditions does trial NCT06586957 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Ovarian Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06586957?
The interventions under investigation include: NKT3964 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06586957?
This trial is sponsored by NiKang Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06586957 being conducted?
This trial has 19 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.